National Cancer Institute Thesaurus

Last uploaded: February 21, 2019
Preferred Name

Botulinum Toxin Type A

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C82623

Accepted_Therapeutic_Use_For

Treatment of cervical dystonia, severe primary axillary hyperhidrosis, Glabellar lines, blepharospasm, strabismus

ALT_DEFINITION

A drug used to treat certain medical conditions. These include severe underarm sweating and severe muscle spasms in the neck and shoulders. OnabotulinumtoxinA is also used to smooth wrinkles on the face. It is being studied in the treatment of pain in patients with skin leiomyomas (benign smooth muscle tumors) and other conditions. It is a form of a toxin made by the bacterium Clostridium botulinum..

A toxin made by the bacterium Clostridium botulinum. It can cause food poisoning. The drug Botox is a form of the toxin that can be used in small amounts to treat certain medical conditions. These include severe underarm sweating and severe muscle spasms in the neck and shoulders. Botulinum toxin type A is also used to smooth wrinkles on the face. It is being studied in the treatment of pain in patients with skin leiomyomas (benign smooth muscle tumors) and other conditions.

CAS_Registry

93384-43-1

code

C82623

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

FDA

DEFINITION

An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular transmission inhibitory and analgesic activities. Upon injection into the affected muscle, the heavy chain portion of botulinum toxin type A (BTX-A) binds to the cell membrane of the motor nerve and is internalized via endocytosis. Upon entry, the light chain portion of the toxin is activated and cleaves the protein SNAP-25, thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, so, the release of ACh into the neuromuscular junction; subsequent binding of ACH to motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction are thus blocked. In addition to ACh, BTX-A may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity.

Display_Name

Botulinum Toxin Type A

FDA_UNII_Code

E211KPY694

FULL_SYN

AbobotulinumtoxinA

Botulinum Neurotoxin Type A

Dysport

Xeomin

Botox Cosmetic

Botulinum Toxin A

BTX-A

IncobotulinumtoxinA

Onaclostox

Botulinum A Toxin

OnabotulinumtoxinA

Botox

EvabotulinumtoxinA

label

Botulinum Toxin Type A

Legacy_Concept_Name

Botulinum_Toxin_Type_A

PDQ_Closed_Trial_Search_ID

634923

PDQ_Open_Trial_Search_ID

634923

Preferred_Name

Botulinum Toxin Type A

prefixIRI

C82623

prefLabel

Botulinum Toxin Type A

Semantic_Type

Pharmacologic Substance

Amino Acid, Peptide, or Protein

UMLS_CUI

C0006050

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C296

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/MEDLINEPLUS/C0006050 MedlinePlus Health Topics LOOM
http://purl.obolibrary.org/obo/CHEBI_3160 Chemical Entities of Biological Interest Ontology LOOM